-
AbbVie’s Allergan Aesthetics Launches Juvéderm VOLUX in China
•
Allergan Aesthetics, a subsidiary of AbbVie (NYSE: ABBV), has announced the official market launch of its Juvéderm VOLUX dermal filler product in China. Juvéderm VOLUX is a hyaluronic acid-based product specifically designed for contouring the lower jaw area. It is used for injection onto the facial periosteum to enhance the…
-
AbbVie Reports Q3 2024 Revenue Growth, Strength in Immunology and Neuroscience
•
US pharmaceutical company AbbVie (NYSE: ABBV) has announced its financial results for the third quarter ended September 30, 2024, with net revenues of USD 14.46 billion, marking a 4.9% increase year-on-year at constant exchange rates. The US market contributed USD 11.148 billion in sales, while the International Market (excluding the…
-
AbbVie Inks $1.4 Billion Deal to Acquire Alzheimer’s Drug Developer Aliada Therapeutics
•
US pharmaceutical company AbbVie (NYSE: ABBV) has entered into a definitive agreement to acquire all outstanding equity of Aliada Therapeutics, Inc., a fellow US firm, for $1.4 billion in cash. The acquisition includes ALIA-1758, an anti-pyroglutamate amyloid beta (3pE-Aβ) antibody in development for the treatment of Alzheimer’s disease (AD). Aliada’s…
-
AbbVie and Gedeon Richter Expand Partnership to Develop Novel Neuropsychiatric Targets
•
AbbVie (NYSE: ABBV), a leading pharmaceutical company based in the U.S., has announced a licensing agreement with Gedeon Richter Plc, aimed at strengthening the development of new potential targets for neuropsychiatric conditions. This collaboration builds upon the nearly two decades of successful partnership on central nervous system (CNS) projects, which…
-
AbbVie’s Vyalev Wins FDA Approval as First Subcutaneous Levodopa Therapy for Advanced Parkinson’s
•
AbbVie (NYSE: ABBV), a leading pharmaceutical company based in the US, has received approval from the US Food and Drug Administration (FDA) for its drug Vyalev (ABBV-951, foscarbidopa and foslevodopa). Vyalev is indicated for the treatment of motor fluctuations in adults with advanced Parkinson’s disease (PD). This approval positions Vyalev…
-
NMPA Clears AbbVie’s ABBV-706 for Clinical Trials Targeting SCLC and Neuroendocrine Tumors
•
The China National Medical Products Administration (NMPA) has granted clinical trial approval to ABBV-706, a novel antibody-drug conjugate (ADC) developed by AbbVie (NYSE: ABBV), for the treatment of relapsed/refractory small cell lung cancer (SCLC) and other neuroendocrine tumors . ABBV-706 is a targeted therapy that binds to SEZ6, a protein…
-
AbbVie Submits First BLA for c-Met Targeting ADC Telisotuzumab Vedotin to FDA
•
AbbVie Inc. (NYSE: ABBV), a leading pharmaceutical company in the U.S., has announced the filing of a first Biologics License Application (BLA) for telisotuzumab vedotin (Teliso-V), a first-in-class antibody-drug conjugate (ADC) targeting tumors that overexpress the c-Met protein. The U.S. Food and Drug Administration (FDA) has accepted the filing for…
-
AbbVie Accuses BeiGene of Trade Secret Theft in BTK Degrader Dispute
•
AbbVie Sues BeiGene Over Alleged Trade Secret Theft in BTK Degrader ProgramU.S. pharmaceutical titan AbbVie Inc. (ABBV) has initiated legal proceedings against BeiGene Ltd. (NASDAQ: BGNE; HKG: 6160; SHA: 688235), accusing the Chinese biotech firm of pilfering trade secrets vital to its Bruton’s tyrosine kinase (BTK) degrader program. According to…
-
AbbVie Completes Acquisition of Cerevel Therapeutics in $8.7 Billion Deal
•
US pharmaceutical giant AbbVie Inc. (NYSE: ABBV) has announced the successful completion of its acquisition of Cerevel Therapeutics (Nasdaq: CERE), a biotech company based in Cambridge, Massachusetts. AbbVie will pay $45.00 per share for Cerevel, totaling an approximate acquisition value of $8.7 billion. The transaction, initially announced in December 2023,…
-
AbbVie’s Allergan Aesthetics Wins NMPA Approval for Juvéderm Dermal Filler in China
•
Allergan Aesthetics, a subsidiary of AbbVie (NYSE: ABBV), has secured marketing approval from China’s National Medical Products Administration (NMPA) for its Juvéderm product line, specifically the Juvéderm越致 dermal filler. This crosslinked sodium hyaluronate gel, which includes lidocaine for comfort during treatment, is designed for injection into the middle to deep…
-
AbbVie’s Q2 2024 Results Show Resilience Amid Humira Biosimilar Challenges
•
AbbVie Inc. (NYSE: ABBV) has reported its financial results for the second quarter of 2024, demonstrating a solid year-on-year (YOY) growth of 5.6% in constant currency terms, reaching $14.462 billion in revenue. The company’s long-standing blockbuster drug, Humira (adalimumab), continues to face biosimilar competition, resulting in a 28.9% YOY decline…
-
Sionna Therapeutics Secures Cystic Fibrosis Portfolio in Licensing Deal with AbbVie
•
US-based biotechnology company Sionna Therapeutics has announced a significant licensing agreement with fellow US firm AbbVie Inc. (NYSE: ABBV), through which Sionna has acquired rights to two Phase II molecules and one Phase I candidate. These pipeline candidates are all modulators designed to treat cystic fibrosis (CF). The deal includes…
-
Pfizer and AbbVie Announce Leadership Changes in Global R&D Divisions
•
In significant executive reshuffling, Pfizer Inc. (NYSE: PFE) and AbbVie (NYSE: ABBV) have both announced changes to their top leadership teams, particularly impacting their global research and development divisions. Pfizer’s Dr. Mikael Dolsten has stepped down from his role as Chief Scientific Officer (CSO) and President of Pfizer Research &…
-
Genmab and AbbVie’s Epcoritamab Earns FDA Accelerated Approval for Follicular Lymphoma
•
Genmab A/S (NASDAQ: GMAB), a Danish biotechnology company, and its co-development partner AbbVie (NYSE: ABBV), have announced that the U.S. Food and Drug Administration (FDA) has granted the first approval for Tepkinly/Epkinly (epcoritamab), an off-the-shelf T-cell engaging CD3xCD20-targeted bispecific antibody (BsAb). The molecule has received accelerated approval for the treatment…
-
AbbVie Bolsters Inflammatory Disease Portfolio with Celsius Therapeutics Acquisition
•
AbbVie (NYSE: ABBV), a major U.S. pharmaceutical company, has announced the acquisition of Celsius Therapeutics Inc., a biotechnology firm specialized in developing therapies for anti-inflammatory diseases. The transaction involves a cash payment of USD 250 million to acquire all equity interests in Celsius. Through this acquisition, AbbVie will obtain control…
-
AbbVie’s Skyrizi Secures FDA Approval for Ulcerative Colitis, Expands Treatment Portfolio
•
AbbVie (NYSE: ABBV) has announced that the U.S. Food and Drug Administration (FDA) has approved a new indication for Skyrizi (risankizumab), marking it for use in treating adults with moderate to severely active ulcerative colitis (UC). This approval positions Skyrizi as the first IL-23 specific inhibitor to be approved for…
-
AbbVie Warns Shareholders Against Tutanota’s Unsolicited Mini-Tender Offer
•
Private investment firm Tutanota has launched an unsolicited mini-tender offer to acquire up to 250,000 shares of AbbVie Inc. (NYSE: ABBV) at a price below market value, according to an announcement from the pharmaceutical company last week. AbbVie has made it clear that it does not endorse Tutanota’s offer and…
-
AbbVie Strikes Deal with FutureGen for Global Rights to Next-Gen TL1A Antibody FG-M701
•
AbbVie (NYSE: ABBV), a biopharmaceutical giant based in the US, has announced a licensing agreement with Beijing-based biotech FutureGen Biopharmaceutical Co., Ltd. The agreement centers around FutureGen’s preclinical asset, FG-M701, a next-generation TL1A antibody being developed for the treatment of irritable bowel disease (IBD). In this deal, AbbVie secures exclusive…
-
AbbVie-Calico Partnership Advances with FDA Approval for Fosigotifator Trial in Rare Brain Disorder
•
The US Food and Drug Administration (FDA) has welcomed an experimental therapy, fosigotifator, developed by AbbVie Inc. (NYSE: ABBV) and Calico Life Sciences, into its Rare Disease Therapy Pilot Program. The investigational eIF2B activator is currently undergoing a Phase Ib/II clinical trial for the treatment of vanishing white matter (VWM)…
-
AbbVie’s Telisotuzumab Vedotin Earns Breakthrough Therapy Designation in China for c-Met Positive NSCLC
•
AbbVie Inc. (NYSE: ABBV), a leading pharmaceutical company based in the U.S., has announced that its cutting-edge antibody-drug conjugate (ADC) telisotuzumab vedotin has been granted breakthrough therapy designation (BTD) in China. This designation is for the treatment of advanced or metastatic epidermal growth factor receptor (EGFR) wild-type (WT) non-squamous (NSq)…
